Ubs Group Ag Xtl Biopharmaceuticals LTD Transaction History

Ubs Group Ag

  • $528 Billion
  • Q1 2025

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$0.8 - $3.07 $5,520 - $21,183
6,900 Added 12777.78%
6,954 $19,000
Q4 2023

Feb 09, 2024
SELL
$0.76 - $1.13 $50 - $74
-66 Reduced 55.0%
54 $0
Q3 2023

Nov 09, 2023
BUY
$0.77 - $1.05 $92 - $126
120 New
120 $0
Q4 2022

Feb 08, 2023
BUY
$1.04 - $1.48 $312 - $444
300 New
300 $0
Q2 2022

Aug 10, 2022
SELL
$1.38 - $2.4 $1,120 - $1,948
-812 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$2.13 - $2.91 $1,401 - $1,914
658 Added 427.27%
812 $2,000
Q4 2021

Feb 14, 2022
SELL
$2.63 - $4.41 $7,216 - $12,101
-2,744 Reduced 94.69%
154 $0
Q3 2021

Nov 15, 2021
BUY
$3.43 - $5.2 $9,940 - $15,069
2,898 New
2,898 $13,000
Q2 2021

Aug 13, 2021
SELL
$3.0 - $3.99 $10,572 - $14,060
-3,524 Closed
0 $0
Q1 2021

May 12, 2021
BUY
$2.89 - $4.15 $10,184 - $14,624
3,524 New
3,524 $12,000
Q4 2020

Feb 11, 2021
SELL
$1.83 - $3.17 $1,895 - $3,284
-1,036 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$1.37 - $2.21 $1,419 - $2,289
1,036 New
1,036 $2,000
Q1 2020

May 01, 2020
SELL
$0.9 - $1.64 $1,101 - $2,007
-1,224 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$1.2 - $1.67 $2,524 - $3,513
-2,104 Reduced 63.22%
1,224 $2,000
Q3 2019

Nov 14, 2019
SELL
$1.44 - $2.1 $288 - $420
-200 Reduced 5.67%
3,328 $5,000
Q2 2019

Aug 14, 2019
SELL
$1.95 - $2.5 $5,460 - $7,000
-2,800 Reduced 44.25%
3,528 $7,000
Q1 2019

May 14, 2019
SELL
$1.72 - $2.61 $589 - $895
-343 Reduced 5.14%
6,328 $15,000
Q4 2018

Feb 14, 2019
BUY
$1.43 - $2.98 $308 - $643
216 Added 3.35%
6,671 $12,000
Q3 2018

Nov 14, 2018
BUY
$1.7 - $2.21 $9,797 - $12,736
5,763 Added 832.8%
6,455 $14,000
Q2 2018

Aug 14, 2018
SELL
$1.55 - $2.41 $677 - $1,053
-437 Reduced 38.71%
692 $1,000
Q1 2018

May 15, 2018
BUY
$1.64 - $2.55 $698 - $1,086
426 Added 60.6%
1,129 $2,000
Q4 2017

Feb 14, 2018
SELL
$2.16 - $2.69 $5,047 - $6,286
-2,337 Reduced 76.88%
703 $2,000
Q3 2017

Nov 14, 2017
SELL
$2.4 - $2.84 $31,845 - $37,683
-13,269 Reduced 81.36%
3,040 $7,000
Q2 2017

Aug 14, 2017
BUY
N/A
10,989 Added 206.56%
16,309 $52,000
Q1 2017

Nov 14, 2017
BUY
N/A
5,320
5,320 $14,000

Others Institutions Holding XTLB

# of Institutions
6
Shares Held
447K
Call Options Held
0
Put Options Held
0
View Full List

About XTL BIOPHARMACEUTICALS LTD

XTLB Quotes by TradingView
  • Ticker XTLB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,449,060
  • Market Cap $6.7M
  • Description
  • XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...
More about XTLB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email